Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:42:32.554Z.
Calculation as of: 2026-10-06T16:42:32.554Z.
Quote observation: 2026-10-06T16:40:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0d034b685c23fadaea9476ccc197406393d04780d3c67e2351ab6b6412cf62fb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$59.30M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$60.99M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fractyl Health, Inc. (GUTS) | $58.57M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.79M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $59.30M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.54M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.66M | N/A | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.71M | N/A | 93.25 | 93.25 | 93.25 |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.99M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.77M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $63.02M | 6.69 | 5.29 | 5.29 | 30.61 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
